Report data from the two-dose 25 µg COVID-19 vaccine study in ages 6 months to 5 years
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 24 Feb 2022
- Due
- 31 Mar 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“In the 6 months to 5 years age group, Moderna is studying a two-dose 25 µg primary series, and expects data in the first quarter of 2022.”
What we found
Evidence strength A What the grades mean
The 10-Q filed 2022-05-04 says Moderna announced KidCOVE data in March 2022 showing a robust antibody response to the two-dose 25 µg series, within the Q1 2022 window.
-
A Moderna 10-Q filed 2022-05-04
“In March 2022, we announced the Phase 2/3 KidCOVE study in children 6 months to under 6 years successfully met its primary endpoint.” ✓ confirmed on the page
-
A Moderna 10-Q filed 2022-05-04
“This interim analysis showed a robust neutralizing antibody response in both age groups after a two-dose 25 µg primary series of mRNA-1273 along with a favorable safety profile.” ✓ confirmed on the page
Market reaction: the shares moved -7.1% against the S&P 500 over the three sessions around the disclosure (3 May 2022 to 6 May 2022). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Data from 25 µg two-dose COVID-19 vaccine study in ages 6 months to 5 years
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-MRNA-006180 · Corrections policy